What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection

被引:51
|
作者
Khan, Shahid [1 ]
Kessler, Thomas M. [1 ]
Apostolidis, Apostolos [1 ,3 ]
Kalsi, Vinay [1 ]
Panicker, Jalesh [1 ]
Roosen, Alexander [1 ]
Gonzales, Gwen [1 ]
Haslam, Collete [1 ]
Elneil, Sohier
Fowler, Clare J. [1 ]
Dasgupta, Prokar [1 ,2 ]
机构
[1] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London WC1N 3BG, England
[2] Guys & St Thomas Hosp Natl Hlth Serv Fdn Trust, Dept Urol, London, England
[3] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Urol 2, GR-54006 Thessaloniki, Greece
来源
JOURNAL OF UROLOGY | 2009年 / 181卷 / 04期
关键词
urinary bladder; overactive; botulinum toxin type A; recurrence; catheterization; quality of life; TOXIN TYPE-A; QUALITY-OF-LIFE; URINARY-INCONTINENCE; SINGLE-CENTER; DOUBLE-BLIND; ANTICHOLINERGICS; EXPERIENCE; SYMPTOMS; EFFICACY; IMPACT;
D O I
10.1016/j.juro.2008.11.110
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We documented the effects of intradetrusor injections of botulinum neurotoxin type A (Botox (R)) for refractory idiopathic detrusor overactivity so that prospective patients maybe properly informed about possible improvement in quality of life, the duration of interinjection intervals and the risk of clean intermittent self-catheterization. Materials and Methods: A total of 81 consecutive patients with refractory idiopathic detrusor overactivity treated with intradetrusor injections of 200 U botulinum neurotoxin type A at 20 sites per injection course were evaluated in this prospective, nonrandomized, open label cohort study. The primary outcome was changes in quality of life, as assessed by the short form of the Urogenital Distress Inventory and the Incontinence Impact Questionnaire before and after treatment. Secondary outcomes were the interinjection interval and the need for clean intermittent self-catheterization. Results: After intradetrusor botulinum, neurotoxin type A injections there was significant improvement in quality of life, which was sustained after repeat injections. Mean Urogenital Distress Inventory and Incontinence Impact Questionnaire scores decreased from 56 to 26 and 59 to 21 after injection 1 in 81 patients, from 52 to 30 and 51 to 24 after injection 2 in 24, from 40 to 19 and 43 to 17 after injection 3 in 13, from 44 to 17 and 61 to 15 after injection 4 in 6 and from 51 to 17 and 63 to 14 after injection 5 in 4, respectively. The median interinjection interval was 15, 12, 14 and 13 months between injections 1 and 2, 2 and 3, 3 and 4, and 4 and 5, respectively. Considering a post-void residual urine of greater than 100 ml with lower urinary tract symptoms as the indication for clean intermittent self-catheterization, the overall clean intermittent self-catheterization rate after treatment was 43%. Conclusions: Intradetrusor botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity significantly improved quality of life. This effect was sustained after repeat injection. More than 2 of 5 patients with refractory idiopathic detrusor overactivity required clean intermittent self-catheterization after botulinum neurotoxin type A injections and. all prospective patients should be informed about this.
引用
收藏
页码:1773 / 1778
页数:6
相关论文
共 50 条
  • [21] A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin
    Popat, R
    Apostolidis, A
    Kalsi, V
    Gonzales, G
    Fowler, CJ
    Dasgupta, P
    JOURNAL OF UROLOGY, 2005, 174 (03): : 984 - 989
  • [22] Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: Urodynamic outcome and patient satisfaction
    Ghalayini, Ibrahim Fathi
    Al-Ghazo, Mohammed A.
    NEUROUROLOGY AND URODYNAMICS, 2007, 26 (04) : 531 - 536
  • [23] Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory detrusor overactivity
    Oguma, Keiji
    Lee, Jae-Chul
    Yokoyama, Teruyuki
    Yamamoto, Yumiko
    Sakaguchi, Yoshihiko
    Ma, Shaobo
    Arimitsu, Hideyuki
    TOXICON, 2008, 51 : 41 - 41
  • [24] Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity
    King, Ashley B.
    Rapp, David E.
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (02) : 5657 - 5659
  • [25] Trigonal injection of botulinum toxin type A does not cause vesicoureteral reflux in patients with refractory neurogenic detrusor overactivity
    Gomes, C.
    Mascarenhas, F.
    Cocuzza, M.
    NEUROUROLOGY AND URODYNAMICS, 2007, 26 (05) : 733 - 734
  • [26] 5 YEAR COST ANALYSIS OF INTRA-DETRUSOR INJECTION OF BOTULINUM TOXIN TYPE A AND AUGMENTATION CYSTOPLASTY FOR REFRACTORY NEUROGENIC DETRUSOR OVERACTIVITY
    Padmanabhan, Priya
    Scarpero, Harriette
    Milam, Douglas
    Dmochowski, Roger
    Penson, David
    JOURNAL OF UROLOGY, 2010, 183 (04): : E136 - E136
  • [27] Subjective patient satisfaction after injection of botulinum-A toxin in detrusor overactivity
    Schulte-Baukloh, H
    Weiss, C
    Schobert, J
    Stolze, T
    Stürzebecher, B
    Knispel, HH
    AKTUELLE UROLOGIE, 2005, 36 (03) : 230 - 233
  • [28] BLADDER BASE INJECTION IS AS EFFECTIVE AND SAFE AS BLADDER BODY INJECTION OF BOTULINUM TOXIN A FOR IDIOPATHIC DETRUSOR OVERACTIVITY
    Chen, C. Y.
    Kuo, H. C.
    NEUROUROLOGY AND URODYNAMICS, 2010, 29 (06) : 1074 - 1075
  • [29] BLADDER BASE INJECTION IS AS EFFECTIVE AND SAFE AS BLADDER BODY INJECTION OF BOTULINUM TOXIN A FOR IDIOPATHIC DETRUSOR OVERACTIVITY
    Chen, C. Y.
    Kuo, H. C.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2010, 21 : S270 - S271
  • [30] Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity
    Kalsi, Vinay
    Apostolidis, Apostolos
    Gonzales, Gwen
    Elneil, Sohier
    Dasyupta, Prokar
    Fowler, Clare J.
    EUROPEAN UROLOGY, 2008, 54 (01) : 181 - 187